Literature DB >> 8428337

A comparison of the quality of life of patients with metastatic prostate cancer who received or did not receive hormonal therapy.

H W Herr1, A B Kornblith, U Ofman.   

Abstract

BACKGROUND AND METHODS: The quality of life in patients who elected to receive hormonal therapy for newly diagnosed asymptomatic metastatic prostate cancer was compared with a comparable group of patients who chose to defer immediate intervention. RESULTS AND
CONCLUSIONS: The premise that active therapy, despite its side effects, would improve or maintain the psychosocial quality of life was not substantiated, and the no-therapy group had better physical and sexual functioning.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8428337     DOI: 10.1002/1097-0142(19930201)71:3+<1143::aid-cncr2820711437>3.0.co;2-i

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  16 in total

Review 1.  Prostate cancer in the elderly.

Authors:  Hatzimouratidis Konstantinos
Journal:  Int Urol Nephrol       Date:  2005       Impact factor: 2.370

2.  Hormone use after radiotherapy failure: a survey of Canadian uro-oncology specialists.

Authors:  D Andrew Loblaw; Tom Pickles; Patrick C Cheung; Himu Lukka; Sergio Faria; Laurence Klotz
Journal:  Can Urol Assoc J       Date:  2009-12       Impact factor: 1.862

3.  Pain caused by bone metastasis in endocrine-therapy-refractory prostate cancer.

Authors:  K Akakura; S Akimoto; J Shimazaki
Journal:  J Cancer Res Clin Oncol       Date:  1996       Impact factor: 4.553

4.  Quality of life as a potential predictor for morbidity and mortality in patients with metastatic hormone-refractory prostate cancer.

Authors:  Patrick W Sullivan; Joel B Nelson; Parvez M Mulani; Darryl Sleep
Journal:  Qual Life Res       Date:  2006-08-10       Impact factor: 4.147

Review 5.  A review of quality-of-life evaluations in prostate cancer.

Authors:  S D Sommers; S D Ramsey
Journal:  Pharmacoeconomics       Date:  1999-08       Impact factor: 4.981

Review 6.  Quality of life issues in men undergoing androgen deprivation therapy: a review.

Authors:  Rowan G Casey; Niall M Corcoran; S Larry Goldenberg
Journal:  Asian J Androl       Date:  2012-01-09       Impact factor: 3.285

7.  A multi-attribute model of prostate cancer patient's preferences for health states.

Authors:  G B Chapman; A S Elstein; T M Kuzel; R B Nadler; R Sharifi; C L Bennett
Journal:  Qual Life Res       Date:  1999-05       Impact factor: 4.147

Review 8.  Prostate cancer and health-related quality of life: a review of the literature.

Authors:  David T Eton; Stephen J Lepore
Journal:  Psychooncology       Date:  2002 Jul-Aug       Impact factor: 3.894

9.  Agreement between prostate cancer patients and their clinicians about utilities and attribute importance.

Authors:  Arthur S Elstein; Gretchen B Chapman; Joan S Chmiel; Sara J Knight; Cheeling Chan; Robert B Nadler; Timothy M Kuzel; Amy K Siston; Charles L Bennett
Journal:  Health Expect       Date:  2004-06       Impact factor: 3.377

10.  Cognitive and mood changes in men undergoing intermittent combined androgen blockade for non-metastatic prostate cancer.

Authors:  M M Cherrier; S Aubin; C S Higano
Journal:  Psychooncology       Date:  2009-03       Impact factor: 3.894

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.